Answers are grounded in this paper and cite their sources.
This review will give an overview of the design process behind the development of sialidase inhibitors, which can be used as anti-influenza drugs. Two drugs (Relenza™ and Tamiflu™) are already available as prescription drugs and a third (BCX-1812) is currently undergoing third-phase clinical trials. Also, the use of molecular-modelling techniques in the understanding of the mechanism and the prediction of inhibition of this enzyme is reviewed.
No takes yet. Share an insight, caveat, or question.
Dyason et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: